• Rocket Pharma stocks up on cardiac gene therapies with $53M Renovacor acquisition

    14 days ago - By MedCity News

    Rocket Pharmaceuticals is acquiring Renovacor, a gene therapies developer whose lead program addresses a particular genetic mutation that leads to a type of heart failure. The all-stock deal gives Rocket the opportunity to expand its reach in genetically driven cardiac diseases.
    Read more ...